Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating viloxazine extended-release (Qelbree) for ADHD in preschool-age children (SPN-812) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• QELBREE (viloxazine hydrochloride)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 4 | Status: RECRUITING